You are here:

defibrotide (Defitelio®)

Advice

following a full submission:

defibrotide (Defitelio®) is accepted for use within NHS Scotland.

Indication under review: Treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.

In a phase III open-label study, defibrotide was associated with improved complete response rate and survival in patients with severe VOD, compared with a historical control group.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of defibrotide. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
 

Drug Details

Drug Name: defibrotide (Defitelio®)
SMC Drug ID: 967/14
Indication: treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.
BNF Category:
Sub Category: 2.6 Nitrates calcium-channel blockers and other antianginal drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 June 2014

Back